Therapeutic Proteins

Questions: Discounts, Updates etc.

Pages: 234

Price (Single): £1,999

Price (Departmental): £3,999

Price (Company): £5,999

Publication Date: 2005-02-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Proteins that are engineered in the laboratory for pharmaceutical use are known as therapeutic proteins. The majority of biopharmaceuticals marketed to date are recombinant therapeutic protein drugs. But how much potential does this market have? Will the shortfall in manufacturing capacity dampen its growth? Will the high cost of these drugs ever be reduced? And how imminent is the threat from biogeneric competition? These and many other questions will be answered in this comprehensive 230-page report on the market for therapeutic proteins.

In 2003, the market for therapeutic proteins grew by almost 19% to $37 billion, and is predicted to achieve sales of over $90 billion by 2010. Future growth however depends largely on the industry overcoming a number of hurdles, including drug delivery challenges and cost issues.

Today therapeutic proteins are used to relieve patients suffering from many conditions, including:

  • Various cancers (Monoclonal antibodies, Interferons)
  • Heart attacks, strokes, cystic fibrosis, Gaucher's disease (Enzymes, Blood factors)
  • Diabetes (Insulin)
  • Anaemia (Erythropoietin)
  • Haemophilia (Blood clotting factors)

The leading therapeutic protein treatments in 2003 were:

  • Johnson & Johnson's anaemia treatment Procrit
  • Amgen's anaemia treatment Epogen
  • Schering-Plough's hepatitis treatments Intron A and Peg-Intron


The leading classes of therapeutic proteins in 2003 were:

  • Erythropoietins
  • Monoclonal antibodies
  • Interferons

While the top companies on the market were:

  • Amgen
  • Johnson & Johnson
  • Roche

WHY YOU MUST BUY THIS REPORT?

With over 80 graphs and figures, plus almost 60 tables, this report represents a key tool for companies wishing to enter into or expand in the therapeutic protein market. The reader will be left with a clear idea of:

  • The challenges faced by the therapeutic protein market, and how these are being overcome
    The current and future market leaders in terms of brand, class, category and company, covering the period 2003-2010
  • Therapeutic targets currently being developed in the field and who is responsible for this development
  • The competition that companies will face during the forecast period from current and pipeline products.

Table of Contents

  • Box 7.1 Who are Nastech Pharmaceuticals?

  • Box 7.2 Who are Amarillo Biosciences?

  • LIST OF GRAPHS, TABLES AND FIGURES
  • Graphs
  • Graph 1.1 The Top 20 Therapeutic Proteins by Revenue ($m), 2003
  • Graph 3.1 Cost of Per Patient ($m) of the Top Ten Therapeutic Proteins, 2003
  • Graph 4.1 Revenues ($m) for Newcomers to the Therapeutic Protein Market, 2003-2004
  • Graph 4.2 Revenues ($m) for New Blockbusters on the Market, 2003
  • Graph 4.3 Revenues ($m) for Blockbuster Therapeutic Proteins, 2003
  • Graph 4.4 Global Procrit/Eprex Sales ($m), 2001-2004
  • Graph 4.5 Global Epogen Sales ($m), 2001-2004
  • Graph 4.6 Global Intron A Family Sales ($m), 2001-2004
  • Graph 4.7 Top Ten Winners and Losers in the Global Therapeutic Protein Market by Growth Rate (%), 2003
  • Graph 4.8 Global Aranesp Sales ($m), 2001-2004
  • Graph 4.9 Global Neulasta Sales ($m), 2002-2004
  • Graph 4.10 Global Enbrel Sales ($m), 2001-2004
  • Graph 4.11 Global Sales ($m) of Therapeutic Proteins by Class, 2003
  • Graph 4.12 Class Winners and Losers in the Therapeutic Protein Market by Growth Rate (%), 2003
  • Graph 4.13 Copaxone Sales ($m) by Company, 2001-2004
  • Graph 4.14 Market Shares (%) for Anti-Arthritic Therapeutic Proteins, 2003-2004
  • Graph 4.15 Winners and Losers in the Therapeutic Protein Market by Growth Rate (%), according to Therapeutic Category, 2003
  • Graph 4.16 Top Ten Companies in the Therapeutic Protein Market by Revenue ($m), 2003
  • Graph 4.17 Amgen's Annual R&D Expenditure ($m), 1993-2003
  • Graph 4.18 Company Winners and Losers in the Therapeutic Protein Market by Growth Rate (%), 2003
  • Graph 5.1 Forecast of Global Procrit/Eprex Sales ($m), 2004-2010
  • Graph 5.2 Forecast of Global Epogen Sales ($m), 2004-2010
  • Graph 5.3 Forecast of Global Aranesp Sales ($m), 2004-2010
  • Graph 5.4 Forecast of Global NeoRecormon Sales ($m), 2004-2010
  • Graph 5.5 Forecast of Global Epogin Sales ($m), 2004-2010
  • Graph 5.6 Forecast of Global Espo Sales ($m), 2004-201
  • Graph 5.7 The Global Market ($m) for Erythropoietins, 2004 Versus 2010
  • Graph 5.8 The Global Market ($m) for Erythropoietins, 2010
  • Graph 5.9 CAGR (%) for the Global Erythropoietins Market, 2004-2010
  • Graph 5.10 Forecast for the Global Erythropoietins Market ($m), 2004-2010
  • Graph 6.1 Global Revenues ($m) for MAbs by Class, 2003
  • Graph 6.2 Global Revenues ($m) for MAbs by Indication, 2003
  • Graph 6.3 Global Sales ($m) of Remicade by Company, 2004-2010
  • Graph 6.4 Global Rituxan Sales ($m), 2004-2010
  • Graph 6.5 Global Herceptin Sales ($m) by Company, 2004-2010
  • Graph 6.6 Global Humira Sales ($m), 2004-2010
  • Graph 6.7 Global Zevalin Sales ($m), 2004-2010
  • Graph 6.8 Global Bexxar Sales ($m), 2004-2010
  • Graph 6.9 Global Avastin Sales ($m), 2004-2010
  • Graph 6.10 Global Erbitux Sales ($m), 2004-2010
  • Graph 6.11 Global Sales ($m) of Selected Monoclonal Antibodies, 2010
  • Graph 6.12 CAGRs (%) for Selected Monoclonal Antibodies, 2004-2010
  • Graph 6.13 Total Global Revenue ($bn) for the MAb Market, 2004-2010
  • Graph 7.1 Global Sales ($m) of the Intron A Family Versus Pegasys, 2004-2010
  • Graph 7.2 Global Intron A Family Sales ($m), 2004-2010
  • Graph 7.3 Global Sales ($m) of Interferons for Multiple Sclerosis, 2004-2010
  • Graph 7.4 Best-Selling Interferons ($m), 2010
  • Graph 7.5 CAGRs (%) for the Best-Selling Interferons, 2004-2010
  • Graph 7.6 Total Global Revenues ($bn) for the Interferon Market, 2004-2010
  • Graph 8.1 Global Humulin and Humalog Sales ($m), 2004-2010
  • Graph 8.2 Global Lantus Sales ($m), 2004-2010
  • Graph 8.3 Global Levemir Sales ($m), 2004-2010
  • Graph 8.4 Global Apidra Sales ($m), 2004-2010
  • Graph 8.5 Global Exubera Sales ($m), 2005-2010
  • Graph 8.6 Global Insulin Sales ($m), 2010
  • Graph 8.7 CAGRs (%) for Insulins, 2004-2010
  • Graph 8.8 Total Global Revenues for the Insulin Market ($m), 2004-2010
  • Graph 9.1 The Global CSF Market ($m), 2004-2010
  • Graph 10.1 Global Revenues ($m) for Blood Factor Brands 2004 Versus 2010
  • Graph 10.2 The Global Blood Factor Market ($m), 2004 Versus 2010
  • Graph 10.3 Global Revenue ($m) for Therapeutic Vaccines, 2004 and 2010
  • Graph 10.4 Global Revenue ($m) for Growth Hormones, 2004 Versus 2010
  • Graph 10.5 The Global Enzyme Market ($m), 2004 vs. 2010
  • Graph 10.6 Global Enbrel Revenue ($m) by Company, 2004 vs. 2010
  • Graph 10.7 Global Sales ($m) for Copaxone Versus Competitor Therapeutic Proteins for MS, 2004-2010
  • Graph 11.1 Top Ten Therapeutic Proteins Globally by Revenue ($m), 2010
  • Graph 11.2 Revenue ($m) for Therapeutic Proteins by Class, 2010
  • Graph 11.3 CAGRs (%) for Classes of Therapeutic Protein, 2003-2010
  • Graph 11.4 Global Revenues ($m) for Therapeutic Proteins by Therapeutic Category, 2010
  • Graph 11.5 Top Ten Companies by Revenue ($m) in the Therapeutic Protein Market, 2010
  • Graph 12.1 Total Revenue ($m) for the Therapeutic Protein Market, 2003-2010
  • Tables
  • Table 1.1 Top 3 Classes, Therapeutic Categories and Indications for Therapeutic Proteins by Revenue, 2003
  • Table 2.1 Examples of Diseases that Therapeutic Proteins Treat
  • Table 3.1 Methods of Administration (MoA) for the Top Ten Therapeutic Proteins (2003)
  • Table 3.2 Features of the Top Ten Therapeutic Proteins (2003), Relevant to Cost
  • Table 3.3 Barriers to Overcome and Entry Strategies to Compete Successfully in the Biogenerics Market
  • Table 3.4 Manufacturing: Make or Buy?
  • Table 3.5 Drivers and Restraints of the Therapeutic Protein Market, 2005
  • Table 4.1 The Global Therapeutic Protein Market ($m), 2002-2003
  • Table 4.2 Top 20 Therapeutic Proteins by Revenue ($m), 2003
  • Table 4.3 Newcomers to the Global Therapeutic Protein Market, 2003
  • Table 4.4 Revenues ($m) for Blockbuster Therapeutic Proteins, 2003
  • Table 4.5 Revenue ($m) for Arthritis Medications in the Top 100, 2003
  • Table 4.6 Revenue ($m) for Classes of Therapeutic Protein, 2003
  • Table 4.7 Top Therapeutic Categories for Therapeutic Proteins by Revenue ($m), 2003
  • Table 4.8 Blood Modifying Therapeutic Proteins by Class and Revenue ($m), 2003
  • Table 4.9 Global Revenues ($m) for Multiple Sclerosis Therapeutic Proteins, 2003
  • Table 4.10 Global Revenues ($m) for Anti-Arthritic Therapeutic Proteins, 2003
  • Table 4.11 Revenues and Market Shares (%) for Anti-Arthritic Therapeutic Proteins, 2003-2004
  • Table 4.12 Revenues ($m) for Hormonal Treatments on the Therapeutic Proteins Market, 2003
  • Table 4.13 Amgen's Therapeutic Proteins by Global Revenues ($m), 2003
  • Table 4.14 Roche's Therapeutic Proteins by Global Revenues ($m), 2003
  • Table 4.15 Wyeth's Therapeutic Proteins by Global Revenues ($m), 2003
  • Table 5.1 Global Erythropoietin Revenue ($m), 2003
  • Table 5.2 The Erythropoietin Pipeline, 2005
  • Table 5.3 The Global Market ($m) for Erythropoietins, 2004-2010
  • Table 6.1 The Global MAb Market ($m), 2003
  • Table 6.2 Classes and Indications of MAbs on the Market, 2003
  • Table 6.3 Selected MAbs in Late-Stage Development, 2005
  • Table 6.4 Selected MAbs in Early-Stage Development, 2005
  • Table 6.5 Global Sales ($m) of Monoclonal Antibodies, 2004-2010
  • Table 7.1 Indications of Currently Marketed Interferons, 2005
  • Table 7.2 The Global Interferon Market ($m), 2003
  • Table 7.3 The Interferon Pipeline, 2005
  • Table 7.4 Global Interferon Revenues ($m), 2004-2010
  • Table 8.1 Insulin Treatments on the Top 400 Market, 2003
  • Table 8.2 Selected Products in the Insulin Pipeline, 2005
  • Table 8.3 Total Global Insulin Sales ($m), 2004-2010
  • Table 9.1 The Global CSF Market ($m), 2003
  • Table 9.2 The CSF Pipeline, 2005
  • Table 9.3 Value of the Global CSF Market ($m), 2004-2010
  • Table 10.1 The Global Blood Factors Market ($m), 2003
  • Table 10.2 The Blood Factor Pipeline, 2005
  • Table 10.3 Global Revenues ($m) for the Top-Selling Blood Factors, 2004 and 2010
  • Table 10.4 The Therapeutic Vaccine Pipeline, 2005
  • Table 10.5 Global Revenues ($m) for Therapeutic Vaccines 2004 Versus 2010
  • Table 10.6 The Global Market ($m) for Growth Hormones, 2003
  • Table 10.7 The Growth Hormone Pipeline, 2005
  • Table 10.8 Global Revenues ($m) for Growth Hormones, 2004 Versus 2010
  • Table 10.9 The Global Enzyme Market ($m), 2003
  • Table 10.10 The Enzyme Pipeline, 2005
  • Table 10.11 Global Revenue ($m) for Enzymes, 2004 vs. 2010
  • Table 10.12 Positions for Anti-Arthritic Therapeutic Proteins, 2003 and 2009
  • Table 10.13 Global Copaxone Sales ($m), 2004-2010
  • Table 11.1 Top Ten Therapeutic Proteins Globally by Revenue ($m), Including Co- Marketing Splits, 2010
  • Table 11.2 Top Ten Therapeutic Proteins Globally by Revenue ($m), Excluding Co-Marketing Splits, 2010
  • Table 11.3 Revenue ($m) for Therapeutic Proteins by Class, 2010
  • Table 11.4 CAGRs (%) for Classes of Therapeutic Protein, 2003-2010
  • Table 11.5 Global Revenues ($m) for Therapeutic Proteins by Therapeutic Category, 2010
  • Table 11.6 Top Ten Companies in the Therapeutic Protein Market Globally by Revenue ($m), 2010
  • Table 11.7 The Global Therapeutic Proteins Market ($m), 2010
  • Table 12.1 Therapeutic Proteins in the Pipeline with Non-Parenteral Methods of Delivery, 2005
  • Figures
  • Figure 4.1 The Market Share (%) for All Blockbuster Therapeutic Proteins, 2003
  • Figure 4.2 Global Market Shares (%) for the Top-Selling Therapeutic Proteins, 2003
  • Figure 4.3 Global Market Shares (%) for Therapeutic Proteins by Class, 2003
  • Figure 4.4 Market Shares (%) in the Global Therapeutic Protein Market by Company, 2003
  • Figure 5.1 The Erythropoietin Feedback Loop
  • Figure 6.1 Protocol for the Production of Monoclonal Antibodies (Anti-Snake Venom)
  • Figure 6.2 Global Market Shares (%) for MAb Classes, 2003
  • Figure 6.3 Global Market Shares (%) for MAbs by Indication, 2003
  • Figure 11.1 Global Market Shares (%) for the Top Ten Therapeutic Proteins, 2010
  • Figure 11.2 Global Market Shares (%) for Classes of Therapeutic Protein, 2010
  • Figure 11.3 Global Market Shares (%) for Categories of Therapeutic Protein, 2010
  • Figure 11.4 Global Market Shares (%) for the Top Ten Companies in the Therapeutic Protein Market, 2010

    • Other users found this report page using the following search terms: Therapeutic Proteins therapeutic proteins protein therapeuticproteins list therapeuticprotein what market examples listoftherapeuticproteins

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.


    Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.